rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).
|
31751012 |
2020 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The first generation tyrosine kinase inhibitors targeting L858R mutated EGFR are routinely used to treat non-small cell lung cancer (NSCLC).
|
30727906 |
2020 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The first generation tyrosine kinase inhibitors targeting L858R mutated EGFR are routinely used to treat non-small cell lung cancer (NSCLC).
|
30727906 |
2020 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).
|
31751012 |
2020 |
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The first generation tyrosine kinase inhibitors targeting L858R mutated EGFR are routinely used to treat non-small cell lung cancer (NSCLC).
|
30727906 |
2020 |
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).
|
31751012 |
2020 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletions and exon 21 L858R substitutions are the most common mutations, accounting for approximately 90% mutations in NSCLC; these are termed classic mutations and result in high sensitivity to tyrosine kinase inhibitors (TKIs).
|
31367543 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Collectively, compound <b>13</b>, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation.
|
31718182 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Secondary acquired mutant EGFR (L858R-T790M) overexpressed NSCLC forms one of the prevalent form of resistant NSCLC.
|
31078412 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21.
|
31327643 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
|
31050691 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The antiproliferative activity of a dual PI3K/mTOR inhibitor BEZ235 was examined by the WST-1 assay and the soft agar colony-formation assay in 2 normal cell lines and 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations.
|
31262325 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63).
|
31466227 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The L858R one-point mutation in exon 21 in EGFR is the most prevalent in NSCLC.
|
30593826 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab.
|
31393548 |
2019 |
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
To assess the utility of the <b>cobas</b> EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with <i>EGFR</i>-mutated (<i>EGFR</i>m; Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125).
|
31439584 |
2019 |